herbal dietary supplement

100% Dried Leaf Material (DLA) of Artemisia annua


Atelier Temenos llc, recognizes the need for quality assurances (Q/A) within the botanical products industry and have added Q/A plus standardization practices from propagation to manufacturing within its cGAP certified Artemisia Nursery and cGMP certified Artecinua™ manufacturing facilities, located in Homestead, FL, USA. Artecinua™ is handcrafted in small batches to maintain purity, authenticity and strength as a non-GMO cultivar, ‘dried leaf Artemisia annua’ (DLA). Artemisia annua’s natural combination of artemisinin, multiple flavonoids and terpenes provide a very high level of therapeutic efficiency and is being verified within clinical trials.

Artemisia Annua, Artemisinin & 2015 Nobel Prize
in Medicine – A Cancer Fighting Plant.
– Mihaela Catalina Stanciu Foundation for Life.

Artemisia annua L. (Sweet Wormwood) is a recognized FDA/GRAS herbal used throughout Asia and Africa as a ‘dried leaf material’ (DLM) in teas and now capsules to treat malaria plus related symptoms (fever, chills). One of its active ingredients, artemisinin (ARS), has been developed and used worldwide as artemisinin combination therapy (ACT), an anti-malarial drug. But it is expensive to produce, is in short supply in areas hit hardest by the disease and the malaria parasite is showing signs of resistance to ACT, particularly in Southeast Asia.*

* This statement has not been evaluated by the Food and Drug Administration.

Traditional application and modern pharmacological research of Artemisia annua L.

As a Traditional Chinese Medicine, Artemisia annua L. (A. annua) has been used for the treatment of various diseases since ancient times, including intermittent fevers due to malaria, bone steaming and heat/fever arising from exhaustion, tuberculosis, lice, wounds, scabies, dysentery et al. With the discovery of artemisinin and its excellent anti-malarial activity, A. annua has received great attention. Recently, A. annua has been revealed to show inhibitory effects against parasites (e.g. Plasmodium, Toxoplasma gondii, Leishmania, Acanthamoeba, Schistosoma), viruses (e.g. hepatitis A virus, herpes simplex viruses 1 and 2, human immunodeficiency virus), fungi (Candida, Malassezia, Saccharomyces spp.) and bacteria (Enterococcus, Streptococcus, Staphylococcus, Bacillus, Listeria, Haemophilus, Escherichia, Pseudomonas, Klebsiella, Acinetobacter, Salmonella, Yersinia spp.). A. annua has also been reported to possess anti-inflammatory and anti-cancer actions and been employed for the treatment of osteoarthritis, leukemia, colon cancer, renal cell carcinoma, breast cancer, non-small cell lung cancer, prostate cancre and hepatoma. Besides, the immunoregulation, anti-adipogenic, anti-ulcerogenic, anti-asthmatic, anti-nociceptive and anti-osteoporotic activities of A. annua were also evaluated. Along these lines, this review summarizes the traditional application and modern pharmacological research of A. annua, providing novel insights of A. annua in the treatment of various diseases.

X. Feng, S. Cao, F. Qiu, B. Zhang. 2020 Traditional application and modern pharmacological research of Artemisia annua L., Pharmacology & Therapeutics,

Interestingly, the bioactivity of A. annua is not restricted to malaria treatment.

Apart from the active compound Artemisinin, recent studies show that A annua is one of the four medical plants with the highest Oxygen Radical Absorbance Capacity (ORAC) levels.

Artemisia annua possess the capacity to produce high phenolic compounds, which result in high antioxidant activity. Five major groups (coumarins, flavones, flavonols, phenolic acids and other miscellaneous) containing over 50 different compounds were identified analyzing A. annua.

Flavonoids are generally known for their redox properties involved in the delay or inhibition of the initiation or propagation on oxidizing chain reactions. Even though the beneficial effect of theses phenolic compounds in association of a great number of diseases is often discussed, different studies show beneficial effects of flavonoids compounds produced by Artemisia annua towards cardiovascular disease, cancer and parasitic diseases. Recent Worcester Polytechnic Institute research includes positive tuberculosis efficiency and a John Hopkins Bloomberg School of Public Health clinical trial included A. annua as one of their effective ‘ethobotanical medicines’ against Lyme disease. In addition A. annuais known in the scientific literature due to its antibacterial, antiviral and antifungal properties.

Today, it has been proven that dried leaves of the A. annua plant (DLM) delivers 40 times more artemisinin in the blood than does the drug based on the chemical extract of the plant, that it is more effective in knocking out protozoan parasites and reduces the level of parasite infection. It constitutes a robust natural combination therapy, one whose benefits far surpass those of ACT and other combination drugs. (1)

Worcester Polytechnic Institute’s (WPI) Professor Pamela Weathers says the superior performance of A. annua DLA in comparison to ACT, as well as, its ability to kill drug-resistant parasites and avoid the resistance trap, itself, is likely due to the synergistic effects of a complex array of phytochemicals contained in the plant’s leaves,

100% Artemisia annua DLA capsule

Based on the reports from the Weathers lab at WPI, Artecinua™ captures the synergistic effects of the whole A. annua plant’s dried leaves (DLA), there are no other commercial A. annua DLA capsules available globally. Extracts of A. annua focus primarily upon limited active ingredients; however, delivery and absorption levels are questionable. A. annua teas are very effective, however, preparation and quality control of the tea is an issue.

Safety and dosage

A. annua,  is classified as a ‘generally regarded as safe’ (GRAS) herb and has been consumed by humans and used as an herbal therapy for thousands of years. Typically A. annua has been consumed as a tea. Prof. Weathers whose work with A. annua for over 25 years, became intrigued by the potential for using the dried plant, rather than just a chemical extract for medicinal treatments. A study she published in Photochemistry Reviews in 2011 was the first to demonstrate that dried leaves of the A. annua plant (DLA) delivers 40 times more artemisinin to the blood than does the drug based on the chemical extract of the plant.

To further the verification of safety and dosage of A. annua DLA:  In 2017, 18 patients with severe malaria, two even in coma, were treated with powdered dried Artemisia leaves (DLA) and cured as reported in a cluster of case studies (2). DLA showed greater efficacy vs. artemisinin combination therapy (ACT) and intravenous artesunate to cure malaria with no adverse side effects.

Artecinua™ will continue to be evaluated for future dosage as more studies emerge.

Quality Assurance (Q/A)

Artecinua™ is a protocol controlled product with cGAP (Good Agricultural Practice) certification from AmeriCert International and cGMP (Good Manufacturing Practice) certification from ASI. There are no A. annua products on the commercial market that can meet those Q/A certifications, globally. Each A. annua DLA batch is Q/A protocol level analyzed for artemisinin and flavonoid content at the Plant Chemical Ecology Lab, within Florida International University. Miami, Fl.  Further microbial and heavy metal analyses are done at the Kaycha Lab, in Miami, Florida. Thus all aspects of propagation to bottling of Artecinua™ are locally validated as ‘Made in the USA’. Our cGMP manufacturing facility is designed exclusively for Artecinua™, for further Q/A assurances.

Artecinua™ availability

For the present Artecinua™ will be available for case study, clinical trials, and medical providers, only. It is the intent of atelier temenos llc, to continue providing the quality assurances that have initiated the development of Artecinua™, so as to be able to reach a global need addressing ‘natural product’ efficacy against tropical diseases, at an affordable price.

Artecinua Label

(1) Dried Leaf Artemisia Annua Improves Bioavailability of Artemisinin via Cytochrome P450 Inhibition and Enhances Artemisinin Efficacy Downstream:

Matthew R Desrosiers1Alexis Mittelman2Pamela J Weathers

(2) Dried Leaf Artemisia (DLA) Compared to Artemisinin Combination Therapy (ACT) vs Malaria:

Daddy NB, Kalisya LM, Bagire PG, Watt RL, Towler MJ, Weathers PJ